These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1399943)

  • 21. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
    Berthaud N; Huet Y; Diallo N; Desnottes JF
    J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics.
    Fox PM; Lampen RJ; Stumpf KS; Archer GL; Climo MW
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2951-6. PubMed ID: 16940087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.
    Tattevin P; Saleh-Mghir A; Davido B; Ghout I; Massias L; Garcia de la Maria C; Miró JM; Perronne C; Laurent F; Crémieux AC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1157-62. PubMed ID: 23254435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.
    Fantin B; Leclercq R; Ottaviani M; Vallois JM; Maziere B; Duval J; Pocidalo JJ; Carbon C
    Antimicrob Agents Chemother; 1994 Mar; 38(3):432-7. PubMed ID: 8203835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.
    Sullam PM; Täuber MG; Hackbarth CJ; Chambers HF; Scott KG; Sande MA
    Antimicrob Agents Chemother; 1985 May; 27(5):685-7. PubMed ID: 3860185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis.
    Perdikaris G; Giamarellou H; Pefanis A; Donta I; Karayiannakos P
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2289-94. PubMed ID: 8619584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1990 Feb; 34(2):257-60. PubMed ID: 2327773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats.
    Cantoni L; Wenger A; Glauser MP; Bille J
    J Infect Dis; 1989 May; 159(5):989-93. PubMed ID: 2708846
    [No Abstract]   [Full Text] [Related]  

  • 37. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases.
    Sgarabotto D; Cusinato R; Narne E; Scano F; Zignol M; Gambino A; Cattelan A; Meneghetti F; Cadrobbi P
    Scand J Infect Dis; 2002; 34(2):122-6. PubMed ID: 11928842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Carpenter TC; Hackbarth CJ; Chambers HF; Sande MA
    Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Maserati R; Cagni AE; Segú C
    Chemotherapy; 1996; 42(2):133-9. PubMed ID: 8697888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.